Previous Close | 2.0000 |
Open | 2.0000 |
Bid | 0.0000 |
Ask | 2.3500 |
Strike | 5.00 |
Expire Date | 2025-03-21 |
Day's Range | 1.6300 - 2.0000 |
Contract Range | N/A |
Volume | |
Open Interest | 7 |
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces three abstracts to be presented at the European Hematology Association (EHA) Congress, June 13-16, 2024. “We are looking forward to presenting longer-term data from adult patients with r/r ALL treated with obe-cel in the FELIX study,” said Dr. Christian Itin, Chief Executive Officer of Autolus. “The d
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other interventionOngoing CAR T persistence was associated with improved event-free survivalAutolus will host a conference call and webcast to discuss the presented data on Saturday June 1, 2024 at 9:30 am EDT/8:30 am CDT/2:30 pm BST (details below) LONDON, May 31, 2024 (GL
Q1 2024 Autolus Therapeutics PLC Earnings Call